Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 90

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 90
---
 million MRSA infections annually in the U.S. [8]. While Vancomycin is standard therapy, resistance
and treatment failures are increasing, prompting interest in second-line options including liposomal Amphotericin B [9].

Liposomal-Mupirocin IV is positioned to target
serious systemic MRSA infections, especially in Vancomycin-resistant or refractory cases.

Pricing Benchmark and Market Assumptions

Vancomycin (per injection): ~$170

| - | Liposomal Amphotericin B (per dose): ~$341 [10], per course $4,500-8,000 |

| - | Liposomal Mupirocin IV pricing assumptions: ~$220 per dose, $1540-3,000 
 per course.                                                             |

| - | Assumed average pricing per course: ~$2,200 |

<div align='center'>55</div>

Epidemiology and Market Size

U.S. incidence of MRSA:

Based on an estimated 32 invasive MRSA cases per 100,000 people
[10], the U.S. (population ~330 million) has approximately 106,000 such cases annually

U.S. TAM for invasive infections:

106,000 × $2,200 = ~$230 million/year

Estimated annual revenue potential at 30% market penetration: ~$70
million

Global Total Addressable Market (TAM):

The global market is assumed at roughly 3 times the size of the
U.S. market at around $690 million.

Estimated global annual revenue potential at 20% market penetration:
~$130+ million

Based on the epidemiological data and pricing assumptions outlined
above, the following table summarizes our estimates for the total addressable market (TAM) and serviceable available market (SAM) for
liposomal mupirocin.

|                                   | Indication |              | Target   
 Pathogen |   | U.S. Target 
 Market Size 
  assumption |   |     |   |     Global 
     Market 
 assumption |   |     |   |   Est. Avg 
      Price 
 Assumption 
   p/course |     |   |    20-30% 
    Market 
   Revenue 
 Potential |   |
|:----------------------------------|:-----------|:-------------|:---------|:--|------------:|:--|:----|:--|-----------:|:--|:----|:--|-----------:|:----|:--|----------: